Vor Biopharma (NASDAQ:VOR) Shares Climb 7.2% - Time to Buy?

Key Points

• Vor Biopharma shares rose 7.2% to about $20.10, although trading volume was 88% below the average session volume.
• Analyst sentiment improved, with two rating upgrades to “hold” and Wedbush raising its price target to $27; the broader consensus remains “Moderate Buy” with a $38 average target.
• The company missed quarterly EPS estimates, reporting a loss of $0.80 versus the expected $0.69, while institutional investors own a substantial 97.29% of outstanding shares.

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report)'s share price rose 7.2% during trading on Thursday. The stock traded as high as $20.02 and last traded at $20.0950. 122,578 shares were traded during mid-day trading, a decline of 88% from the average session volume of 1,057,865 shares. The stock had previously closed at $18.75.

Analyst Ratings Changes

Several research analysts recently commented on the stock. Wall Street Zen upgraded shares of Vor Biopharma from a "sell" rating to a "hold" rating in a report on Saturday, August 15th. Weiss Ratings upgraded shares of Vor Biopharma from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Monday, September 14th. Finally, Wedbush upped their price objective on shares of Vor Biopharma from $18.00 to $27.00 and gave the company a "neutral" rating in a research note on Wednesday, August 12th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $38.00.

Vor Biopharma Stock Up 4.3%

The firm's 50 day moving average is $21.77 and its two-hundred day moving average is $18.34.

Vor Biopharma (NASDAQ:VOR - Get Free Report) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.11). On average, research analysts anticipate that Vor Biopharma Inc. will post -2.56 EPS for the current fiscal year.

Institutional Investors Weigh In On Vor Biopharma

Hedge funds and other institutional investors have recently made changes to their positions in the business. Engineers Gate Manager LP boosted its stake in Vor Biopharma by 37.5% during the second quarter. Engineers Gate Manager LP now owns 36,951 shares of the company's stock worth $680,000 after buying an additional 10,071 shares during the period. Cannon Global Investment Management LLC acquired a new stake in Vor Biopharma in the 1st quarter valued at about $209,000. Sei Investments Co. purchased a new stake in shares of Vor Biopharma in the 1st quarter valued at approximately $245,000. Independent Financial Group LLC acquired a new position in Vor Biopharma during the first quarter worth $249,000. Finally, Wellington Management Group LLP acquired a new stake in Vor Biopharma during the 2nd quarter worth approximately $499,000. Hedge funds and other institutional investors own 97.29% of the company's stock.

Vor Biopharma Company Profile

Vor Biopharma Inc is a clinical-stage biotechnology company focused on developing engineered hematopoietic stem cell and targeted immunotherapy treatments for cancer, particularly hematologic malignancies such as acute myeloid leukemia (AML). The company's approach is designed to combine gene-edited blood stem cells with targeted therapies intended to improve the ability to treat disease while protecting healthy blood-forming cells.

Vor's technology platform has included engineered hematopoietic stem cells designed to remove or alter specific cell-surface targets, along with targeted immunotherapies intended to eliminate malignant cells that retain those targets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.